# NCT02819518 (NCT02819518)

> Study of Pembrolizumab (MK-3475) Plus Chemotherapy vs. Placebo Plus Chemotherapy for Previously Untreated Locally Recurrent Inoperable or Metastatic Triple Negative Breast Cancer (MK-3475-355/KEYNOTE-355)

No report yet. It can be ordered.

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT02819518
- Phase: PHASE3
- Status: COMPLETED
- Sponsor: Merck Sharp & Dohme LLC
- Conditions: Triple Negative Breast Cancer (TNBC)
- Interventions: Pembrolizumab; Nab-paclitaxel; Paclitaxel; Gemcitabine; Carboplatin; Normale Saline Solution
- Enrollment: 882
- Primary outcome: Part 1: Percentage of Participants Who Experienced an Adverse Event (AE) - All Participants
- Primary outcome: Part 1: Percentage of Participants Who Discontinued Study Drug Due to an AE - All Participants
- Primary outcome: Part 2: Progression-Free Survival (PFS) - All Participants
- Primary outcome: Part 2: PFS - Participants With Programmed Cell Death-Ligand 1 (PD-L1) Combined Positive Score (CPS) ≥1 Tumors
- Primary outcome: Part 2: PFS - Participants With PD-L1 CPS ≥10 Tumors
- Primary outcome: Part 2: Overall Survival (OS) - All Participants
- Primary outcome: Part 2: OS - Participants With PD-L1 CPS ≥1 Tumors
- Primary outcome: Part 2: OS - Participants With PD-L1 CPS ≥10 Tumors

## Commentary we found

- YouTube: 70
- Podcasts: 55
- X threads: 6

## Order

Deep, $1,950, price fixed at order: https://www.erudio.com/contact?report=nct02819518

## Free build

POST https://www.erudio.com/api/trial-requests with {"nct_id": "NCT02819518", "email": "<work email>"}; the inbox owner confirms by the emailed link.